BioNTech and partner Duality Biologics reported that their HER2-targeting antibody-drug conjugate (ADC), trastuzumab pamirtecan, achieved the primary endpoint of progression-free survival in a Phase III interim analysis for patients with HER2-positive unresectable or metastatic breast cancer previously treated with trastuzumab and taxane-based chemotherapy. This milestone marks BioNTech’s first Phase III oncology success and may lead to a Biologics License Application in China, bolstering their breast cancer treatment portfolio against competitors.